MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why VERA Stock slipped -1.32% Today — RQD Quant Desk Flash
$30.53 -1.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $30.40
Vera Therapeutics Inc. (Class A) (VERA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $2.20B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $30.40 (-0.43%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VERA)Realized 20D OHLCV Swing Band: ±12.2%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY VERA SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)
FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 52.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$29.88-6.7% Next Q
27
Q2 (-2Q)Grade E$27.88+0.4% Next Q
30
Q3 (-1Q)Grade E$27.99+9.1% Next Q
32
CurrentGrade D-$30.53-8.5% Hist 90D α
35
Trajectory: E (27) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VERA Turnaround Squeeze
While VERA currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.00) and Max Pain ($32.06) forces dealer call-delta covering toward $58.85.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VERA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VERA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VERA Stock slipped -1.32% Today — RQD Quant Desk Flash
Vera Therapeutics Inc. (Class A) (VERA) slipped -1.32% to $30.53, trading at 23% of its 52-week range ($23.05 – $56.05). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 23% of its 52-week range ($23.05 – $56.05) with RSI-14 at 52.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.2% around $30.53 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VERA Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VERA)
- ✓Walkthrough of VERA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VERA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.27%▼ DESCENDING CHANNEL
2026-10-30O $30.30H $31.29L $29.56C $30.53VOL 1.08M
RES: $32.33SUP: $25.69SMA50: $32.00SMA200: $36.96
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VERA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VERA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VERA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VERA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VERA)
Health Care Rank #811 of 1016
⚔️ MRVI vs VERA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VERA vs. MRVI, PRGO, PVLA, AGIO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vera Therapeutics Inc. (Class A) (VERA) ranks #811 by composite RQD confidence (35/100, grade D-) and #244 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, VERA leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. PVLA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with VERA at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VERA
ACTIVE
Vera Therapeutics Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -1.32% | $2.20B | Benchmark Subject |
| MRVI Maravai LifeSciences Holdings Inc. (Class A) | D- | 36/100 | — | 18.3% | -35.0% | -0.47% | $2.20B | /mrvi-vs-vera → |
| PRGO Perrigo Company plc | D- | 41/100 | — | 35.1% | -13.6% | -0.13% | $2.21B | /prgo-vs-vera → |
| PVLA Palvella Therapeutics Inc. | D | 46/100 | — | — | -27.9% | +2.79% | $2.18B | /pvla-vs-vera → |
| AGIO Agios Pharmaceuticals Inc. | D- | 39/100 | — | 88.3% | -33.8% | -2.33% | $2.22B | /agio-vs-vera → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001831828In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vera Therapeutics Inc. (Class A) (VERA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$299.6M, operating cash flow of -$241.1M, and free cash flow of -$241.7M (-78.2% YoY). On the balance sheet, VERA closed FY2025 with $734.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$299.6M | -$241.1M | -$241.7M | $734.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$152.1M | -$134.7M | -$135.7M | $655.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$96.0M | -$92.2M | -$92.2M | — | — |
3. VERA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VERA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Vera Therapeutics Inc. (Class A) (NASDAQ: VERA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $30.53 (-1.32% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VERA ranks #811 in composite RQD confidence.
How does VERA compare to MRVI and PRGO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and PRGO (Perrigo Company plc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -13.6%, cap $2.21B). Among the 5-stock peer group, VERA leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VERA?
Per VERA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831828), Vera Therapeutics Inc. (Class A) generated $0 in revenue, -$299.6M in net income, and -$241.7M in free cash flow against $734.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VERA trading relative to its 50-day, 200-day, and 52-week technical levels?
VERA last traded at $30.53 (-1.32% on volume of 1,108,679 shares), positioning the stock -4.59% below its 50-day simple moving average ($32.00) and -17.40% below its 200-day simple moving average ($36.96). Across its 52-week range of $23.05 to $56.05, VERA sits at the 22.7% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($26.81 to $34.25).
VERA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VERA stock moving today?
Why VERA Stock slipped -1.32% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.